Innovative T Cell-Targeted Therapy for Ovarian Cancer
Abstract
Major advances have been made in two main areas. Firstly, Receptor tyrosine kinase-like orphan receptor-1 (ROR1) was identified as a tumor antigen expressed on ovarian cancer (OvCa), but not expressed on normal tissue(s). Second generation chimeric antigen receptors (CARs) were designed with CD3z and either CD28 or CD137 endodomains fused to the antigen-binding region of a ROR1-specific monoclonal antibody (clone 4A5). CARs were stably expressed in T cells following Sleeping Beauty transposition and propagation on ROR1+ artificial antigen presenting cells (aAPC). Re-directed cytolysis of ROR1+ OvCa cell lines by CAR+ T cells was demonstrated. Secondly, the anti-tumor activity of y delta T cells was harnessed to kill OvCa. aAPC were used to expand a polyclonal population of y delta T cells for immunotherapy. OvCa xenografts were eliminated by polyclonal y delta T cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA591080
Entities
People
- Laurence Cooper
Organizations
- The University of Texas MD Anderson Cancer Center